Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting

January 14, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates

January 09, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function

January 06, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President

January 04, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

January 03, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:

Via Benzinga

Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 03, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022 ↗

January 03, 2022

Upgrades For nVent Electric PLC (NYSE:NVT), Vertica...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗

December 31, 2021

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...

Via Benzinga

51 Biggest Movers From Yesterday ↗

December 28, 2021

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 27, 2021

Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%...

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

December 27, 2021

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY...

Via Benzinga

BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops ↗

December 27, 2021

Patients who received the drug didn't improve in the six-minute walking test.

Via Investor's Business Daily

FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol ↗

December 23, 2021

The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is...

Via Benzinga

The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review ↗

December 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...

Via Benzinga

Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C

December 22, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy

December 22, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies

December 21, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗

December 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...

Via Benzinga

Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease

December 20, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout

December 20, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022 ↗

December 14, 2021

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ...

Via Benzinga

Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1

December 14, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021

December 02, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming Investor Conferences

November 23, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock ↗

November 22, 2021

RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M...

Via Benzinga

How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022 ↗

November 22, 2021

Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.

Via Investor's Business Daily

Expert Ratings For Alnylam Pharmaceuticals ↗

November 22, 2021

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021 ↗

November 22, 2021

Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE:

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.